Amylin Pharmaceuticals
Latest Amylin Pharmaceuticals News
-
Google, Monster, Manpower Are Big Market Movers
analysts downgraded the search engine company, saying its heavy spending on new products will hurt margins. Amylin Pharmaceuticals Inc ., up 51 cents at $14.22 The company said its diabetes medication appears safe for the heart, addressing
-
EU Approves Lilly's Weekly Diabetes Drug Bydureon
Tuesday. Eli Lilly and Co., Amylin Pharmaceuticals Inc . and Alkermes Inc. said they Bydureon is a version of Lilly and Amylin 's diabetes drug Byetta, which formulation of Bydureon. Lilly, Amylin and Alkermes plan to submit that
-
Icahn Nominates 4 Candidates to Forest Labs Board
backed nominee was added to the board in 2010. Denner was also elected to the board of Amylin Pharmaceuticals Inc . in 2009 as part of a proxy contest in which Amylin 's chairman and another key board member were replaced with nominees backed by Icahn
-
Court Denies Injunction on Lilly in Amylin Case
that a federal court denied an Amylin Pharmaceuticals Inc . request for a preliminary injunction headquartered in Indianapolis. Amylin , which is based in San Diego and sell a competing product. Amylin and Lilly entered an agreement
-
Summary Box: Lilly Receives Restraining Order
INJUNCTION FUNCTION: Amylin Pharmaceuticals Inc . said Thursday a federal court the same sales force to sell an Amylin -developed type 2 diabetes treatment with the order. THE BIG PICTURE: Amylin and Lilly entered an agreement in
-
Court Issues Restraining Order Against Eli Lilly
Amylin Pharmaceuticals Inc . said Thursday a federal court issued using the same sales force to sell an Amylin -developed diabetes treatment and a competitor's. Amylin , which is based in San Diego, said
News
-
Health Highlights: Jan. 13, 2010
misleading materials. Among the specific concerns cited by the FDA, according to Dow Jones : Representatives of Amylin Pharmaceuticals and Eli Lilly exaggerated the ability of the diabetes drug Byetta to help patients lose weight. A print ad for
-
FDA Issues Warning for Diabetes Drug
these symptoms to immediately consult with a health-care professional. Byetta, made by San Diego-based Amylin Pharmaceuticals Inc ., is used to control blood sugar levels. Nausea, vomiting and diarrhea are the most common side effects
-
Curbing Obesity Epidemic Key to Health Care Reform: Experts
public and private organizations. The alliance is funded by drug makers Sanofi-Aventis U.S. L.L.C. and Amylin Pharmaceuticals . Former Surgeon General Dr. David Satcher, whose 2001 report on obesity recognized the problem as an "epidemic
-
Diabetes Drug Byetta May Aid Weight Loss in Obese Patients
Society in Washington, D.C. Previous research has shown that exenatide, an injectable medication marketed by Amylin Pharmaceuticals and Eli Lilly and Company under the brand name Byetta, can help lower blood sugar and helps some diabetics lose
-
Health Highlights: May 5, 2009
injectable diabetes drug exenatide LAR has been submitted to the U.S. Food and Drug Administration for approval, Amylin Pharmaceuticals Inc . said Tuesday. The drug is an extended version of the twice-daily injectable drug Byetta, the Associated
-
New Diabetes Drug Works Well in Trial
S. market. The first is exenatide (Byetta), which was approved by the FDA in 2005. It is marketed by Amylin Pharmaceuticals and Eli Lilly. It is taken by injection twice a day, while liraglutide requires only one daily injection
-
Once-Weekly Diabetes Drug Boosts Blood Sugar Control
heels of less-heartening news about Byetta (exenatide). On Aug. 26, the drug's makers, Eli Lilly and Amylin Pharmaceuticals Inc ., reported the pancreatitis-linked deaths of four people who'd been taking the medication. That news
